|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.3187 - 0.3420|
|52 Week Range||0.3070 - 0.7600|
|Beta (5Y Monthly)||-22.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
GENEVA, SWITZERLAND / ACCESSWIRE / February 24, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development, announces that NeuroRx, Inc. has reported data from the Phase 2b/3 trial of RLF-100(TM) for the treatment of Respiratory Failure in Critical COVID-19 patients.
NeuroRx, Inc. announced today that the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its prespecified primary endpoint of Recovery from Respiratory Failure with discharge from hospital and ICU (without relapse) by day 28 in patients with critical Covid-19 who were treated with High Flow Nasal Oxygen. Although not envisioned at the start of the clinical trial, High Flow Nasal Oxygen has become the predominant form of treatment in Covid-19 respiratory failure, with mechanical ventilation reserved for those whose blood oxygen levels cannot be maintained on this less invasive modality. The trial was conducted at 10 U.S. hospitals under the direction of NeuroRx in collaboration with RELIEF THERAPEUTICS Holding AG (SIX: RLF; OTCQB: RLFTF). NeuroRx has signed an agreement to complete a business combination with Big Rock Partners Acquisition Corporation (NASDAQ:BRPA).
Initial results have been presented by Relief's partner, NeuroRx, Inc.; additional statistical analyses remain ongoing and shall be presented when completeGENEVA, SWITZERLAND / ACCESSWIRE / February 10, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF)("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the release of preliminary results from the phase 2b/3 trial of intravenously administered RLF-100(TM) by its partner NeuroRx, Inc.